Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNCA
Previous Symbol
CUSIPN/A
Phone617-876-8191
Debt
Debt-to-Equity Ratio1.91
Current Ratio4.01
Quick Ratio4.01
Price-To-Earnings
Trailing P/E Ratio-0.29
Forward P/E Ratio-1.29
P/E GrowthN/A
Sales & Book Value
Annual Sales$230,000.00
Price / Sales218.65
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book8.29
Profitability
EPS (Most Recent Fiscal Year)($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-584.35%
Return on Assets-96.12%
Miscellaneous
Employees52
Outstanding Shares86,630,000
Market Cap$53.27 million
OptionableOptionable
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) issued its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.09) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.01. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
What price target have analysts set for GNCA?
4 Wall Street analysts have issued 1-year price objectives for Genocea Biosciences' stock. Their predictions range from $3.00 to $5.00. On average, they expect Genocea Biosciences' share price to reach $4.00 in the next year. This suggests a possible upside of 589.1% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.
What is the consensus analysts' recommendation for Genocea Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (11/8/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (11/1/2018)
- 3. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)
Has Genocea Biosciences been receiving favorable news coverage?
Headlines about GNCA stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Genocea Biosciences earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Idera Pharmaceuticals (IDRA), Neon Therapeutics (NTGN), Nantkwest (NK), Allena Pharmaceuticals (ALNA), Compugen (CGEN), Jounce Therapeutics (JNCE), Erytech Pharma (ERYP), Champions Oncology (CSBR), Eiger Biopharmaceuticals (EIGR), Pluristem Therapeutics (PSTI), Organovo (ONVO), Applied Genetic Technologies (AGTC), Fennec Pharmaceuticals (FENC), Cidara Therapeutics (CDTX) and BioCardia (BCDA).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 49)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 73)
- Dr. Darren Higgins, Scientific Co-Founder & Member of Scientific Advisory Board
- Mr. Michael Alfieri, Principal Financial Officer & Principal Accounting Officer (Age 53)
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 46)
Who are Genocea Biosciences' major shareholders?
Genocea Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fosun International Ltd (0.47%) and Renaissance Technologies LLC (0.23%). Company insiders that own Genocea Biosciences stock include George Siber, Jonathan Poole, Michael Alfieri and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Which institutional investors are buying Genocea Biosciences stock?
GNCA stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd and Renaissance Technologies LLC. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $0.5805.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $53.27 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.
What is Genocea Biosciences' official website?
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
